viral
respiratori
infect
vri
frequent
hematopoiet
stem
cell
transplant
constitut
potenti
caus
mortal
analyz
incid
risk
factor
prognosi
vri
cohort
transplant
patient
frequent
virus
human
coronaviru
human
rhinoviru
follow
flulik
virus
adenoviru
risk
factor
death
lymphocytopenia
high
steroid
dosag
common
viral
respiratori
infect
vri
import
caus
morbid
mortal
allogen
hematopoiet
cell
transplant
hsct
vri
includ
respiratori
syncyti
viru
rsv
influenza
viru
parainfluenza
viru
piv
human
adenoviru
adv
human
rhinoviru
hrv
recent
metapneumoviru
mpv
coronaviru
hcov
prospect
routin
sought
center
incid
rang
depend
type
viru
detect
method
time
transplant
present
singlecent
studi
report
incid
clinic
featur
outcom
vri
period
transplant
patient
patient
underw
first
allogen
hsct
center
decemb
august
regularli
follow
center
elig
includ
studi
clinic
biolog
data
extract
local
databas
complet
chart
review
studi
period
decemb
june
patient
respiratori
symptom
possibl
relat
respiratori
viru
nasopharyng
aspir
pcr
multiplex
viral
analysi
design
detect
rsv
type
b
adv
hrv
human
mpv
hcov
influenza
viru
type
b
differ
bacteria
chlamydophila
pneumonia
mycoplasma
pneumonia
legionella
pneumophila
bordetella
pertussi
bacteri
fungal
infect
document
usual
method
includ
bronchoalveolar
lavag
patient
suspicion
pneumonia
virus
divid
group
hrv
hcov
share
benign
symptomatolog
common
cold
low
direct
mortal
rate
thu
compil
one
group
given
wors
occas
fatal
outcom
posttranspl
set
rsv
mpv
piv
influenza
viru
infect
gather
second
flulik
group
adv
alloc
separ
third
group
dissemin
patient
analyz
base
first
episod
vri
accord
viru
speci
group
death
consid
compet
event
vri
cumul
incid
vri
estim
use
usual
methodolog
first
vri
viru
first
vri
group
virus
associ
baselin
characterist
risk
vri
analyz
use
cox
proport
causespecif
hazard
model
model
involv
vri
differ
viru
group
patient
whether
time
robust
sandwich
estim
varianc
paramet
use
account
potenti
correl
patient
level
given
patient
followup
timetoev
data
censor
month
transplant
analys
perform
use
r
statist
softwar
version
median
followup
month
vri
diagnos
patient
median
month
hsct
among
patient
diagnos
outpati
vri
distribut
follow
adv
hcovhrv
flulik
includ
influenza
viru
piv
rsv
human
mpv
characterist
patient
vri
shown
tabl
clinic
present
vri
differ
differ
viru
type
copathogen
present
case
threeyear
cumul
incid
vri
estim
confid
interv
ci
figur
hazard
infect
adv
markedli
lower
viru
group
p
wherea
infect
hcov
hrv
frequent
infect
flulik
virus
p
risk
factor
identifi
univari
analysi
first
vri
hcovhrv
infect
histori
acut
graftversushost
diseas
gvhd
hazard
ratio
hr
ci
p
chronic
gvhd
hr
ci
p
contrast
highrisk
diseas
ne
p
cord
blood
stem
cell
sourc
hr
ci
p
donorerecipi
hla
mismatch
hr
ci
p
risk
factor
adv
malign
cord
blood
stem
cell
sourc
hr
ci
p
gvhd
hr
ci
p
risk
factor
flulik
virus
patient
infect
vri
die
within
month
among
death
patient
die
viral
pneumonia
concomit
anoth
caus
death
bacteri
andor
fungal
pneumonia
rsv
n
adv
n
uncontrol
gvhd
adv
hrv
n
rsv
n
hcov
n
graft
reject
bacterialfung
pneumonia
rsv
n
adv
n
posttranspl
lymphoprolif
diseas
hcov
n
univari
analysi
risk
factor
death
month
identifi
activ
gvhd
odd
ratio
ci
p
ongo
steroid
therapi
dose
mgkg
bodi
weight
higher
ci
p
lymphocyt
count
lower
gl
ci
p
pneumonia
time
diagnosi
ci
p
presenc
copathogen
ci
p
interestingli
viru
group
time
hsct
impact
mortal
multivari
analys
show
factor
remain
associ
increas
overal
mortal
steroid
dose
mgkg
bodi
weight
ci
p
lymphocyt
count
lower
gl
ci
p
figur
overal
incid
vri
studi
consist
incid
report
team
use
pcr
detect
viral
infect
ie
higher
immunofluoresc
viral
cultur
higher
incid
hcovhrv
compar
vri
confirm
find
milano
et
al
howev
unlik
systemat
sampl
milano
studi
sampl
collect
patient
respiratori
symptom
patient
present
mild
symptom
probabl
seek
medic
attent
often
sever
infect
select
bia
explain
patient
vri
studi
seem
similar
clinic
present
includ
similar
pneumonia
preval
underestim
gener
vri
incid
studi
includ
patient
follow
year
transplant
show
vri
continu
occur
high
frequenc
late
posttranspl
phase
overal
longterm
data
vri
allogen
hsct
limit
martino
et
al
report
incid
vri
detect
immunofluoresc
viral
cultur
close
activ
gvhd
defin
gvhd
partial
complet
remiss
pneumonia
defin
new
pulmonari
infiltr
imageri
z
copathogen
defin
second
infect
includ
opportunist
cytomegaloviru
bacteri
fungal
infect
result
year
versu
year
studi
viru
repartit
differ
lower
frequenc
hrv
attribut
lower
sensit
detect
method
previou
acut
chronic
gvhd
recipientedonor
hla
mismatch
consid
surrog
marker
immun
increas
probabl
vri
diagnosi
suggest
patient
suscept
vri
previous
describ
predispos
factor
viral
infect
final
mortal
rate
attribut
vri
high
expect
associ
particular
viru
studi
caus
death
could
clearli
conclud
vri
patient
die
viral
pneumonia
signific
potenti
fatal
comorbid
observ
risk
factor
mortal
vri
patient
steroid
dose
lymphopenia
report
studi
although
discrimin
risk
factor
specif
patient
vri
common
transplant
patient
inde
steroid
lymphopenia
reflect
poor
gener
condit
patient
sever
gvhd
andor
delay
immun
reconstitut
vri
risk
factor
overal
mortal
cohort
one
argu
immun
statu
might
impact
infect
data
shown
noteworthi
longterm
studi
time
transplant
vri
effect
prognosi
probabl
gener
statu
patient
higher
impact
outcom
final
although
direct
mortal
rate
appear
low
keep
mind
fatal
vri
occur
sever
immunocompromis
patient
furthermor
exclud
later
complic
indirectli
caus
vri
increas
late
mortal
noninfecti
respiratori
diseas
secondari
organ
failur
conclud
estim
nasopharyng
aspir
identifi
vri
patient
respiratori
symptom
restrict
patient
profound
immun
defect
lower
respiratori
tract
involv
could
benefit
care
clinic
monitor
recoveri
